JP2004513616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004513616A5 JP2004513616A5 JP2002505816A JP2002505816A JP2004513616A5 JP 2004513616 A5 JP2004513616 A5 JP 2004513616A5 JP 2002505816 A JP2002505816 A JP 2002505816A JP 2002505816 A JP2002505816 A JP 2002505816A JP 2004513616 A5 JP2004513616 A5 JP 2004513616A5
- Authority
- JP
- Japan
- Prior art keywords
- morbillivirus
- mutation
- amino acids
- group
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21365500P | 2000-06-23 | 2000-06-23 | |
| PCT/US2001/019806 WO2002000694A2 (en) | 2000-06-23 | 2001-06-21 | Modified morbillivirus v proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004513616A JP2004513616A (ja) | 2004-05-13 |
| JP2004513616A5 true JP2004513616A5 (enExample) | 2008-08-07 |
Family
ID=22795965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002505816A Pending JP2004513616A (ja) | 2000-06-23 | 2001-06-21 | 改変モルビリウイルスタンパク質 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6664066B2 (enExample) |
| EP (1) | EP1292615B1 (enExample) |
| JP (1) | JP2004513616A (enExample) |
| KR (1) | KR100885325B1 (enExample) |
| CN (1) | CN1298738C (enExample) |
| AT (1) | ATE343589T1 (enExample) |
| AU (2) | AU2001267014B2 (enExample) |
| BR (1) | BR0111827A (enExample) |
| CA (1) | CA2409432C (enExample) |
| CY (1) | CY1105842T1 (enExample) |
| DE (1) | DE60124098T2 (enExample) |
| DK (1) | DK1292615T3 (enExample) |
| ES (1) | ES2273852T3 (enExample) |
| IL (1) | IL153004A0 (enExample) |
| MX (1) | MXPA02012256A (enExample) |
| PT (1) | PT1292615E (enExample) |
| WO (1) | WO2002000694A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE50214201D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| KR100999316B1 (ko) | 2003-06-09 | 2010-12-10 | 와이어쓰 엘엘씨 | ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법 |
| DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 |
| EP2069485A4 (en) * | 2007-07-13 | 2011-05-25 | Medimmune Llc | PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| MX2010008468A (es) | 2008-01-31 | 2010-08-30 | Curevac Gmbh | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| EP2804948B1 (en) * | 2012-01-20 | 2020-04-15 | The Government of The Hong Kong Special Administrative Region of The People's Republic of China | A novel paramyxovirus and uses thereof |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US10458801B2 (en) | 2014-05-06 | 2019-10-29 | Uber Technologies, Inc. | Systems and methods for travel planning that calls for at least one transportation vehicle unit |
| WO2015171772A1 (en) | 2014-05-06 | 2015-11-12 | Lord Robert W | System and methods for verifying that one or more end user transport directives do not conflict with one or more package delivery directives |
| US11100434B2 (en) | 2014-05-06 | 2021-08-24 | Uber Technologies, Inc. | Real-time carpooling coordinating system and methods |
| US9552559B2 (en) | 2014-05-06 | 2017-01-24 | Elwha Llc | System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user |
| WO2016009044A1 (en) * | 2014-07-18 | 2016-01-21 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Peptides including a binding domain of the viral phosphoprotein (p) subunit to the viral rna free nucleoprotein (n0) |
| WO2016029168A1 (en) | 2014-08-21 | 2016-02-25 | Uber Technologies, Inc. | Arranging a transport service for a user based on the estimated time of arrival of the user |
| US10685416B2 (en) | 2015-12-10 | 2020-06-16 | Uber Technologies, Inc. | Suggested pickup location for ride services |
| US10731998B2 (en) | 2017-11-05 | 2020-08-04 | Uber Technologies, Inc. | Network computer system to arrange pooled transport services |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT702085E (pt) | 1994-07-18 | 2004-04-30 | Karl Klaus Conzelmann | Virus de arn de cadeia negativa nao segmentada infeccioso recombinante |
| ATE181112T1 (de) | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
| CA2265554A1 (en) * | 1996-09-27 | 1998-04-02 | American Cyanamid Company | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales |
| BR9809456B1 (pt) | 1997-05-23 | 2011-06-28 | molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica. | |
| JP2002507408A (ja) * | 1998-03-26 | 2002-03-12 | アメリカン・サイアナミド・カンパニー | 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異 |
-
2001
- 2001-06-21 CA CA2409432A patent/CA2409432C/en not_active Expired - Fee Related
- 2001-06-21 ES ES01944623T patent/ES2273852T3/es not_active Expired - Lifetime
- 2001-06-21 CN CNB018116426A patent/CN1298738C/zh not_active Expired - Fee Related
- 2001-06-21 PT PT01944623T patent/PT1292615E/pt unknown
- 2001-06-21 JP JP2002505816A patent/JP2004513616A/ja active Pending
- 2001-06-21 DE DE60124098T patent/DE60124098T2/de not_active Expired - Lifetime
- 2001-06-21 IL IL15300401A patent/IL153004A0/xx unknown
- 2001-06-21 KR KR1020027017494A patent/KR100885325B1/ko not_active Expired - Fee Related
- 2001-06-21 US US10/311,582 patent/US6664066B2/en not_active Expired - Fee Related
- 2001-06-21 BR BR0111827-7A patent/BR0111827A/pt not_active Application Discontinuation
- 2001-06-21 DK DK01944623T patent/DK1292615T3/da active
- 2001-06-21 WO PCT/US2001/019806 patent/WO2002000694A2/en not_active Ceased
- 2001-06-21 EP EP01944623A patent/EP1292615B1/en not_active Expired - Lifetime
- 2001-06-21 MX MXPA02012256A patent/MXPA02012256A/es active IP Right Grant
- 2001-06-21 AU AU2001267014A patent/AU2001267014B2/en not_active Ceased
- 2001-06-21 AU AU6701401A patent/AU6701401A/xx active Pending
- 2001-06-21 AT AT01944623T patent/ATE343589T1/de not_active IP Right Cessation
-
2006
- 2006-12-11 CY CY20061101780T patent/CY1105842T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004513616A5 (enExample) | ||
| CA2409432A1 (en) | Modified morbillivirus v proteins | |
| Cattaneo et al. | Biased hypermutation and other genetic changes in defective measles viruses in human brain infections | |
| Bailey et al. | Full genome sequence of peste des petits ruminants virus, a member of the Morbillivirus genus | |
| KR100525687B1 (ko) | 재조합체 센다이바이러스 | |
| Garcia-Barreno et al. | Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions | |
| CN1118569C (zh) | 具有自主复制能力的负链rna病毒载体 | |
| Mazumder et al. | Requirement of casein kinase II-mediated phosphorylation for the transcriptional activity of human respiratory syncytial viral phosphoprotein P: transdominant negative phenotype of phosphorylation-defective P mutants | |
| JP4189035B2 (ja) | 溶解性を向上させた組換えヒトインターフェロン−β | |
| Blumberg et al. | Analysis of the Sendai virus M gene and protein | |
| JP2021508435A (ja) | 改変トランスアミナーゼポリペプチドおよびそれらの使用 | |
| CN110997922B (zh) | 使用双链多联体dna的无细胞蛋白质表达 | |
| JP7083408B2 (ja) | アミノ酸デヒドロゲナーゼ突然変異体及びその応用 | |
| JPWO2020218419A5 (enExample) | ||
| Leyrer et al. | Rapid and efficient recovery of Sendai virus from cDNA: factors influencing recombinant virus rescue | |
| JP2005514003A (ja) | 高いプライミング特異性を有するｄｎａの低温サイクル伸長 | |
| CN1177927C (zh) | 引起麻疹病毒或人呼吸道合胞病毒亚组b减毒的突变 | |
| JP2020535810A (ja) | 改変デカルボキシラーゼポリペプチドおよびβ−アラニンの調製におけるそれらの用途 | |
| CA2289776A1 (en) | An infectious clone for human parainfluenza virus type 3 | |
| JP2024509146A (ja) | コロナウイルスに対して保護するためのワクチン産生のための完全合成長鎖核酸 | |
| AU781343B2 (en) | Lentivirus from the group of immunodeficiency viruses of drill monkeys (Mandrillus leucophaeus) and their use | |
| AU2002366706A1 (en) | Nucleic acid labeling by thermoanaerobacter thermohydrosulfuricus dna polymerase i variants | |
| JP3565579B2 (ja) | ネコ伝染性腹膜炎ｉ型ウイルスのスパイク蛋白質遺伝子ｒｎａに対応するｄｎａ | |
| RU2024110750A (ru) | Вакцины против коронавируса на основе piv5 и способы их применения | |
| JP2002325574A5 (enExample) |